Context Therapeutics Inc

-0.04 (-1.68%)
Earnings Announcements

Context Therapeutics Reports Q1 2022 Operating And Financial Results

Published: 05/11/2022 20:53 GMT
Context Therapeutics Inc (CNTX) - Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results.
Context Therapeutics - Expects That Its Cash and Cash Equivalents Will Be Sufficient to Fund Its Operations Into 2024.
Context Therapeutics - Qtrly Loss per Share $0.22.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.25

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.31

More details on our Analysts Page.